AU7905501A - Apo-2l receptor agonist and cpt-11 synergism - Google Patents

Apo-2l receptor agonist and cpt-11 synergism

Info

Publication number
AU7905501A
AU7905501A AU7905501A AU7905501A AU7905501A AU 7905501 A AU7905501 A AU 7905501A AU 7905501 A AU7905501 A AU 7905501A AU 7905501 A AU7905501 A AU 7905501A AU 7905501 A AU7905501 A AU 7905501A
Authority
AU
Australia
Prior art keywords
synergism
cpt
apo
receptor agonist
2l receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU7905501A
Inventor
Enrique Escandon
Judith A Fox
Sean K Kelley
Hong Xiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US22125600P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to PCT/US2001/023691 priority patent/WO2002009755A2/en
Publication of AU7905501A publication Critical patent/AU7905501A/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
AU7905501A 2000-07-27 2001-07-27 Apo-2l receptor agonist and cpt-11 synergism Withdrawn AU7905501A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US22125600P true 2000-07-27 2000-07-27
PCT/US2001/023691 WO2002009755A2 (en) 2000-07-27 2001-07-27 Apo-2l receptor agonist and cpt-11 synergism

Publications (1)

Publication Number Publication Date
AU7905501A true AU7905501A (en) 2002-02-13

Family

ID=22827042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU7905501A Withdrawn AU7905501A (en) 2000-07-27 2001-07-27 Apo-2l receptor agonist and cpt-11 synergism

Country Status (12)

Country Link
EP (2) EP2014303A2 (en)
JP (1) JP2004509078A (en)
AT (1) AT415978T (en)
AU (1) AU7905501A (en)
CA (1) CA2415473A1 (en)
CY (1) CY1108815T1 (en)
DE (1) DE60136816D1 (en)
DK (1) DK1303293T3 (en)
ES (1) ES2317924T3 (en)
IL (1) IL153948D0 (en)
PT (1) PT1303293E (en)
WO (1) WO2002009755A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc Apo-2 ligand/trail variants and uses thereof
AU2003259835A1 (en) * 2002-08-15 2004-03-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
JP2007530588A (en) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Receptor coupling agent and its therapeutic applications
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (en) * 2005-08-16 2018-05-22 Genentech Inc method for predicting the sensitivity of a cell or tissue sample, the method for inducing apoptosis in a cell or tissue sample and a method of treating a disorder
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974B1 (en) 1978-01-06 1982-12-03 David Bernard
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa New DNA sequences, their application as a sequence encoding a signal peptide for secretion of mature proteins by recombinant yeast expression cassettes, transformed yeasts and method of preparation of proteins corresponding
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc Bispecific reagents for AIDS Therapy
DK0939121T4 (en) 1989-09-12 2008-02-04 Ahp Mfg B V TNF binding proteins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int Production and use of transgenic animals capable of producing lower heterologous antibodies.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
IL99553D0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
RU2139731C1 (en) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Methods of treatment, antibodies, hybridoma
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung A process for ligand binding in vivo selection of proteins.
WO1994029348A2 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Production of antibody fragments
SE9304060D0 (en) 1993-12-06 1993-12-06 Bioinvent Int Ab Method for selecting specific bacteriophages
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
NZ311982A (en) 1995-06-29 1999-08-30 Immunex Corp Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies
DK0859841T3 (en) 1995-08-18 2002-09-09 Morphosys Ag Protein / (poly) peptide libraries
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AT278958T (en) 1996-03-20 2004-10-15 Dyax Corp Cleaning of tissue plasminogen activator (tpa)
AU3135097A (en) 1996-05-22 1997-12-09 Johns Hopkins University, The Methods of detection utilizing modified bacteriophage
EP0918860A2 (en) 1996-06-07 1999-06-02 Amgen Inc. Tumor necrosis factor-related polypeptide
CA2257873A1 (en) 1996-06-10 1997-12-18 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
WO1998005344A1 (en) 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
ES2248823T5 (en) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutrokine alpha.
IL130492A (en) 1996-12-23 2007-09-20 Immunex Corp Antibodies to a receptor activator of nf-kappa b ligand (rankl), methods of preparing the antibodies and compositions comprising them
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
DK0970213T3 (en) 1997-03-17 2007-05-21 Human Genome Sciences Inc Dödsdomæneholdig receptor
PL190092B1 (en) 1997-04-16 2005-10-31 Amgen Inc. Osteoprotegeric bonding proteins and receptors
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
ES2293682T5 (en) 1997-05-15 2011-11-17 Genentech, Inc. Anti-apo2.
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
AU8767698A (en) 1997-08-06 1999-03-01 Procter & Gamble Company, The Novel orphan receptor
WO1999009165A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
JP2002500877A (en) * 1998-01-26 2002-01-15 ジェネンテク・インコーポレイテッド Antibodies and uses thereof to cell death receptor 4 (dr4)
ES2308836T3 (en) * 1998-03-27 2008-12-01 Genentech, Inc. Synergy of anti-HER-2 antibodies and ligands to apo l'-2.
IL146491D0 (en) * 1999-06-09 2002-07-25 Genentech Inc APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
KR20150110923A (en) 2014-03-21 2015-10-05 에스케이플래닛 주식회사 Beacon apparatus for seamless service, and control method thereof

Also Published As

Publication number Publication date
EP2014303A2 (en) 2009-01-14
JP2004509078A (en) 2004-03-25
EP1303293A2 (en) 2003-04-23
WO2002009755A3 (en) 2003-02-13
ES2317924T3 (en) 2009-05-01
AT415978T (en) 2008-12-15
WO2002009755A2 (en) 2002-02-07
EP1303293B1 (en) 2008-12-03
IL153948D0 (en) 2003-07-31
CA2415473A1 (en) 2002-02-07
CY1108815T1 (en) 2014-04-09
DK1303293T3 (en) 2009-03-30
DE60136816D1 (en) 2009-01-15
PT1303293E (en) 2009-03-11

Similar Documents

Publication Publication Date Title
AP1665A (en) Tamper-resistant oral opioid agonist formulations.
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
DK1140145T4 (en) New exendin agonist formulations and methods for administration thereof
PT1212089E (en) Roflumilast and salmeterol synergy combination
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
PL370762A1 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
AU2002366384A8 (en) Insulin and igf-1 receptor agonists and antagonists
DE60112609D1 (en) Pyrazolopyridine
AU5945801A (en) Opoid antagonist compositions and dosage forms
IL153297D0 (en) Compounds and compositions for delivering active agents
SI2014285T1 (en) NPYY5 antagonists
HRP20030466A2 (en) Urea substituted imidazoquinoline ethers
IL134009D0 (en) Implantable device
IL156646D0 (en) Isoindole-imide compounds, compositions, and uses thereof
AU2778801A (en) Antisense compositions and methods
IL160837D0 (en) Toll-like receptor 3 signaling agonists and antagonists
AU2080802A (en) Prosthetic fixing fastener and device for delivering same
EP1244447A4 (en) Novel methods and compositions involving opioids and antagonists thereof
GB0100407D0 (en) Formulation
AU3990901A (en) E-mail notification device
IL152642A (en) Network usage monitoring device and associated method
GB0109768D0 (en) Device
AU9074901A (en) Abutment for dental implant and associated components for use therewith
PT1913939T (en) Formulations for use in inhaler devices
AU6472001A (en) Articulated member surgical device and methods

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted